Market Place
Sourcing Support
Organovo Presents FXR314 Data In Phase 2 MASH At The Liver Meeting
20 Nov 2024 //
GLOBENEWSWIRE
Organovo to Present FXR314 Clinical Data at Liver Meeting
13 Nov 2024 //
GLOBENEWSWIRE
Organovo Highlights FXR314 Value Catalysts At Jones Trading Conference
16 Jul 2024 //
GLOBENEWSWIRE
Organovo Shows FXR314 IBD Combination Potential At DDW2024
21 May 2024 //
GLOBENEWSWIRE
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
08 May 2024 //
GLOBENEWSWIRE
Organovo To Present FXR314 IBD 3D Model Findings at Crohn™s and Colitis Congress
09 Jan 2024 //
GLOBENEWSWIRE
CORRECTION “ Organovo Highlights FXR314 Combination Therapy Potential and Plan
13 Nov 2023 //
GLOBENEWSWIRE
Organovo to Participate in the H.C. Wainwright Global Investment Conference
08 Sep 2023 //
GLOBENEWSWIRE
Organovo Advances Clinical Timelines for FXR314
23 Aug 2023 //
GLOBENEWSWIRE
Organovo Announces FXR Program
21 Mar 2023 //
GLOBENEWSWIRE
Organovo Announces Accelerating Timeline for Crohn’s Drug Candidates
15 Nov 2022 //
GLOBENEWSWIRE
Organovo to Participate in the H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
Organovo Achieves 3D Tissue Model for Crohn`s Disease
17 May 2022 //
GLOBENEWSWIRE
Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
01 Mar 2022 //
GLOBENEWSWIRE
Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
23 Feb 2022 //
GLOBENEWSWIRE
Organovo Welcomes New Sr. Vice President of Strategy and Business Development
18 Feb 2022 //
GLOBENEWSWIRE
Organovo Holdings Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 Feb 2022 //
GLOBENEWSWIRE
Organovo Files Counterclaims In Patent Lawsuit Brought Against It by CellInk
10 Jan 2022 //
GLOBENEWSWIRE
Organovo Announces Adjournment of Annual Meeting of Shareholders
17 Sep 2021 //
GLOBENEWSWIRE
Novo Holdings acquires BBI Group in £400 million deal
15 Jun 2021 //
PHARMAFILE
Tarveda Therapeutics Provides Update on Proposed Merger with Organovo
07 Apr 2020 //
BUSINESSWIRE
Organovo and Tarveda Therapeutics Announce Definitive Merger Agreement
18 Dec 2019 //
BUSINESSWIRE
Viscient Biosciences Proposes Merger to Unlock 3D Bioprinting Potential
02 Oct 2019 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.